Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.

doi:10.1097/JTO.0b013e3181f1c8de

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2010

Pirker Robert, Herth Felix J F, Kerr Keith M, Filipits Martin, Taron Miquel, Gandara David, Hirsch Fred R, Grunenwald Dominique, Popper Helmut, Smit Egbert, Dietel Manfred, Marchetti Antonio, Manegold Christian, Schirmacher Peter, Thomas Michael, Rosell Rafael, Cappuzzo Federico, Stahel Rolf

Abstract excerpt

INTRODUCTION: Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been characterized in a subset of patients with advanced non-small cell lung cancer (NSCLC). Patients harboring these mutations in their tumors show excellent response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The EGFR-TKI gefitinib has been approved in Europe for the treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Clinical Trials as Topic

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Mass Screening

Share to Mutation

Source

Open in PubMed

Identifiers

PMID: 20871269
DOI: 10.1097/JTO.0b013e3181f1c8de

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.PMID 20871269Read ↗

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.Semantic proximity Read ↗

Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.Semantic proximity Read ↗

Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung CancerSemantic proximity Read ↗

EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC.Semantic proximity Read ↗

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.Semantic proximity Read ↗

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.Semantic proximity Read ↗

EGFR mutation testing from liquid biopsy of non-small cell lung cancer at the Institute for Oncology and Radiology of Serbia.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.Semantic proximity Read ↗

Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome.Semantic proximity Read ↗

Clinical Performance Evaluation Of The Idylla™ Egfr Mutation Test On Formalin-Fixed Paraffin-Embedded Tissue Of Non-Small Cell Lung CancerSemantic proximity Read ↗

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.Semantic proximity Read ↗

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.